MicroRNA aberrations:An emerging field for gallbladdercancer management

作     者：Vishal Chandra Jong Joo Kim Balraj Mittal Rajani Rai 

作者机构：Department of Obstetrics and GynecologyStephenson Cancer CenterUniversity of Oklahoma Health Sciences CenterOklahoma CityOK 73104United States Department of BiosciencesIntegral UniversityLucknow 226026(UP)India School of BiotechnologyYeungnam UniversityGyeongsan 712-749South Korea Department of GeneticsSanjay Gandhi Post Graduate Institute of Medical SciencesLucknow 226014India 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2016年第22卷第5期

页      面：1787-1799页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Gallbladder cancer MicroRNA Aberrations Tumor suppressor gene Oncogene Biomarker Therapy 

摘      要：Gallbladder cancer(GBC) is infrequent but most lethal biliary tract malignancy characterized by an advanced stage diagnosis and poor survival rates attributed to absence of specific symptoms and effective treatment options. These necessitate development of early prognostic/predictive markers and novel therapeutic interventions. Micro RNAs(mi RNAs) are small, noncoding RNA molecules that play a key role in tumor biology by functioning like tumor suppressor- or oncogenes and their aberrant expression are associated with the pathogenesis of several neoplasms with overwhelming clinical implications. Since mi RNA signature is tissue specific, here, we focused on current data concerning the mi RNAs abberations in GBC pathogenesis. In GBC, mi RNAs with tumor suppressor activity(mi R-135-5p, mi R-335, mi R-34 a, mi R-26 a, mi R-146b-5p, Mir-218-5p, mi R-1, mi R-145, mir-130a) were found downregulated, while those with oncogenic property(mi R-20 a, mi R-182, mir-155) were upregulated. The expression profile of mi RNAs was significantly associated with GBC prognosis and prediction, and forced over-expression/ inhibition of these mi RNAs was shown to affect tumor growth and development. Further, differential expression of mi RNAs in the blood samples of GBC patients suggest mi RNAs as promising noninvasive biomarker. Thus, mi RNAs represent potential candidate for GBC management, though many hurdles need to be overcome before mi RNAs therapy can be clinically applied to GBC prevention and treatment.